Publication:
Antimalarial drug resistance

dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChurchill Hospitalen_US
dc.date.accessioned2018-07-24T03:54:48Z
dc.date.available2018-07-24T03:54:48Z
dc.date.issued2004-01-01en_US
dc.description.abstractMalaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill between one and two million people, mainly children, each year. Resistance has emerged to all classes of antimalarial drugs except the artemisinins and is responsible for a recent increase in malaria-related mortality, particularly in Africa. The de novo emergence of resistance can be prevented by the use of antimalarial drug combinations. Artemisinin-derivative combinations are particularly effective, since they act rapidly and are well tolerated and highly effective. Widespread use of these drugs could roll back malaria.en_US
dc.identifier.citationJournal of Clinical Investigation. Vol.113, No.8 (2004), 1084-1092en_US
dc.identifier.doi10.1172/JCI21682en_US
dc.identifier.issn00219738en_US
dc.identifier.other2-s2.0-2142659388en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/21747
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=2142659388&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleAntimalarial drug resistanceen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=2142659388&origin=inwarden_US

Files

Collections